加载中
NASDAQHealthcareMedical - Devices
最新数据
US$106.68
−US$0.02 · -0.02%
iRhythm Technologies, Inc. is a digital healthcare enterprise dedicated to offering portable electrocardiogram (ECG) monitoring solutions to individuals in the United States who face the risk of cardiac arrhythmias. Its primary offering, the Zio service, provides a comprehensive ambulatory cardiac monitoring system. This system ingeniously combines a wireless, patch-based, and wearable biosensor—specifically embodied in products like the Zio XT and AT monitors—with a sophisticated cloud-based data analysis platform. These single-use biosensors precisely record a patient's heartbeats and ECG data, thereby enabling medical professionals to effectively oversee patient heart health and accurately diagnose arrhythmias. Furthermore, iRhythm maintains a strategic development partnership with Verily Life Sciences LLC, focused on pioneering future atrial fibrillation screening, detection, and monitoring innovations. Founded in 2006, the company maintains its corporate headquarters in San Francisco, California.
收盘时
US$106.68
−US$0.02 · -0.02%
盘后
US$108.02
+US$1.34 · +1.26%
10月12日 17:09 ET
盘中时间采用ET。市场数据可能有所延迟。
iRhythm Technologies, Inc. is a digital healthcare enterprise dedicated to offering portable electrocardiogram (ECG) monitoring solutions to individuals in the United States who face the risk of cardiac arrhythmias. Its primary offering, the Zio service, provides a comprehensive ambulatory cardiac monitoring system. This system ingeniously combines a wireless, patch-based, and wearable biosensor—specifically embodied in products like the Zio XT and AT monitors—with a sophisticated cloud-based data analysis platform. These single-use biosensors precisely record a patient's heartbeats and ECG data, thereby enabling medical professionals to effectively oversee patient heart health and accurately diagnose arrhythmias. Furthermore, iRhythm maintains a strategic development partnership with Verily Life Sciences LLC, focused on pioneering future atrial fibrillation screening, detection, and monitoring innovations. Founded in 2006, the company maintains its corporate headquarters in San Francisco, California.
日内区间
当前US$106.68
52周区间
当前US$106.68
盘中时间采用ET。市场数据可能有所延迟。
iRhythm Technologies, Inc. is a digital healthcare enterprise dedicated to offering portable electrocardiogram (ECG) monitoring solutions to individuals in the United States who face the risk of cardiac arrhythmias. Its primary offering, the Zio service, provides a comprehensive ambulatory cardiac monitoring system. This system ingeniously combines a wireless, patch-based, and wearable biosensor—specifically embodied in products like the Zio XT and AT monitors—with a sophisticated cloud-based data analysis platform. These single-use biosensors precisely record a patient's heartbeats and ECG data, thereby enabling medical professionals to effectively oversee patient heart health and accurately diagnose arrhythmias. Furthermore, iRhythm maintains a strategic development partnership with Verily Life Sciences LLC, focused on pioneering future atrial fibrillation screening, detection, and monitoring innovations. Founded in 2006, the company maintains its corporate headquarters in San Francisco, California.
日内区间
当前US$106.68
52周区间
当前US$106.68
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 7.47亿 USD | 5.92亿 USD | 4.93亿 USD | 4.11亿 USD | 3.23亿 USD |
| 销货成本 | 2.2亿 USD | 1.84亿 USD | 1.61亿 USD | 1.29亿 USD | 1.09亿 USD |
| 毛利 | 5.27亿 USD | 4.08亿 USD | 3.32亿 USD | 2.82亿 USD | 2.14亿 USD |
| 研究与开发 | 8461万 USD | 1.04亿 USD | 6024.4万 USD | 4661万 USD | 3867.1万 USD |
| 销售、一般及管理费用 | 4.79亿 USD | 4.19亿 USD | 3.86亿 USD | 3.22亿 USD | 2.75亿 USD |
| 营业费用 | 5.64亿 USD | 5.23亿 USD | 4.57亿 USD | 3.95亿 USD | 3.14亿 USD |
| 利息收入 | 2152.1万 USD | 2193.8万 USD | 615.5万 USD | 235万 USD | 11.8万 USD |
| 利息支出 | 1315.4万 USD | 1282.1万 USD | 365万 USD | 413.8万 USD | 116.9万 USD |
| 折旧和摊销 | 2647.9万 USD | 2577.7万 USD | 2214.4万 USD | 1960.9万 USD | 1659.4万 USD |
| 营业利润 | −3681万 USD | −1.16亿 USD | −1.25亿 USD | −1.14亿 USD | −9994.3万 USD |
| 净利润 | −4455.1万 USD | −1.13亿 USD | −1.23亿 USD | −1.16亿 USD | −1.01亿 USD |
公司数据更新于 2026年10月12日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$174.88
上涨空间 63.93%报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI1.22亿0.01%2.3万亿 USD0.03%US$381.57-0.10%
iShares Russell 2000 ETFIWM9200.07万0.12%787.4亿 USD0.19%US$277.9-0.37%
Vanguard Morningstar Small-Cap ETFVB8844.85万0.05%1853亿 USD0.03%US$288.16-0.46%
Vanguard Morningstar Small-Cap Growth ETFVBK5084.83万0.11%447亿 USD0.05%US$340.88-1.12%
Vanguard Extended Market ETFVXF4544.95万0.05%954亿 USD0.05%US$233.52-0.63%
iShares Russell 2000 Growth ETFIWO3262.79万0.23%139.17亿 USD0.24%US$353.71-0.86%
Vanguard Russell 2000 ETFVTWO2264.51万0.12%180亿 USD0.06%US$112.27-0.35%
Schwab U.S. Small-Cap ETFSCHA1853.08万0.08%218.24亿 USD0.03%US$32.66-0.40%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Morningstar Small-Cap ETFVBVanguard Morningstar Small-Cap Growth ETFVBKVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHAAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
